Graft versus leukemia without fatal graft-versus-host disease in AKR mice.
BW 5147 leukemia in AKR mice has been successfully treated by adoptive immunotherapy using allogeneic spleen cells from C57BL/6J mice. Graft-versus-host reaction was prevented by treatment with spleen cells from a second allogeneic strain (CBA, H-2 identical with AKR), followed by cycloposphamide and syngeneic spleen cells. Successful treatment of leukemia without graft-versus-host reaction is dependent upon a close relationship at the H-2 locus between the second allogeneic donor and the host AKR mice, since cells from a non-H-2 identical donor (DBA/2) do not increase survival. The doses of cyclophosphamide and of C57BL/6J spleen cells are also parameters of critical importance in successful treatment.
D000818:Animals; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006087:Graft vs Host Reaction / Q000517:prevention & control*; D006649:Histocompatibility Antigens; D007112:Immunity, Maternally-Acquired; D007167:Immunotherapy; D007942:Leukemia, Experimental / Q000628:therapy; D007945:Leukemia, Lymphoid / Q000628:therapy*; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D008810:Mice, Inbred C57BL; D008808:Mice, Inbred CBA; D008954:Models, Biological; D013154:Spleen / Q000276:immunology / Q000637:transplantation; D014183:Transplantation, Heterologous; D014184:Transplantation, Homologous
D006649:Histocompatibility Antigens; D003520:Cyclophosphamide